"The Report
Mavrilimumab (Rheumatoid Arthritis) - Forecast and Market Analysis to
2023 provides information on pricing, market analysis, shares,
forecast, and company profiles for key industry participants. -
MarketResearchReports.biz"
Description
Mavrilimumab (Rheumatoid
Arthritis) - Forecast and Market Analysis to 2023
Summary
Rheumatoid arthritis (RA) is a
chronic autoimmune disease which causes inflammation and deformity of
the joints . It affects over seven million individuals in the 10MM
covered in this report (US, France, Germany, Italy, Spain, UK, Japan,
Australia, China, and India) and the prevalence is expected to grow
to just over 8.5 million individuals by 2023. The anti-TNFs have been
effective in treating the signs and symptoms of RA and inhibiting
progression to erosive bone disease. However, the landscape is
quickly changing with the introduction of biosimilars, novel
biologics, and a class of oral therapies known as JAK inhibitors, all
of which will change the market dynamics between 2013 and 2023. With
the anti-TNFs as extremely effective therapies for RA, the market is
extremely competitive for new entrants and will undergo further
pressure as biosimilars are approved and launch.
Mavrilimumab, also known as
CAM3001, is in Phase IIb of development for RA by MedImmune, a
subsidiary of AstraZeneca. It is a human mAb targeted against the
alpha subunit of the GM-CSF receptor. GM-CSF levels are elevated in
the serum, synovial fluid, and synoviocytes of patients with RA.
Inhibition of GM-CSF activity is proposed to reduce the activation,
differentiation, and recruitment of macrophages and neutrophils in
the damaged and inflamed joints of RA patients.
View
Full Report at http://www.marketresearchreports.biz/analysis/247170
Scope
- Overview of Rheumatoid
Arthritis, including epidemiology, etiology, symptoms, diagnosis,
pathology and treatment guidelines as well as an overview on the
competitive landscape.
- Detailed information on
Mavrilimumab including product description, safety and efficacy
profiles as well as a SWOT analysis.
- Sales forecast for
Mavrilimumab for the top 6 countries from 2013 to 2023.
- Sales information covered
for the US, France, Germany, Italy, Spain and the UK.
Reasons
to buy
- Understand and capitalize by
identifying products that are most likely to ensure a robust return.
- Stay ahead of the
competition by understanding the changing competitive landscape for
Rheumatoid Arthritis.
- Effectively plan your M&A
and partnership strategies by identifying drugs with the most
promising sales potential.
- Make more informed business
decisions from insightful and in-depth analysis of Mavrilimumab
performance.
- Obtain sales forecast for
Mavrilimumab from 2013-2023 in top 6 countries (the US, France,
Germany, Italy, Spain and the UK).
Download
Detail Report With Complete TOC at
Table
of Content
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 11
2.3 Upcoming Related Reports
14
3 Disease Overview 15
3.1 Etiology and
Pathophysiology 15
3.1.1 Etiology 15
3.1.2 Pathophysiology 15
3.2 Symptoms 20
3.3 Prognosis 21
3.4 Quality of Life 21
4 Disease Management 22
4.1 Diagnosis and Treatment
Overview 22
4.1.1 Diagnosis 22
4.1.2 Treatment Guidelines 24
4.1.3 Leading Prescribed Drugs
for the Treatment of RA 33
4.1.4 Clinical Practice 34
5 Competitive Assessment 40
5.1 Overview 40
6 Unmet Need and Opportunity
42
6.1 Overview 42
6.2 Development of
Cost-Effective Therapies 43
6.2.1 Unmet Need 43
6.2.2 Gap Analysis 44
6.2.3 Opportunity 44
6.3 Biomarkers to Predict
Responsiveness to Therapy 45
6.3.1 Unmet Need 45
6.3.2 Gap Analysis 47
6.3.3 Opportunity 47
7 Pipeline Assessment 54
7.1 Overview 54
Browse
Latest News at http://www.marketresearchreports.biz/articles
About
Us
MarketResearchReports.biz is
the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Browse
Our Press Releases by Prnewswire:
http://www.prnewswire.com/news/marketresearchreports.biz
Contact
Us
Office:
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA: Canada Toll Free:
866-997-4948
No comments:
Post a Comment